Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.En Ze Jia Shi Pharmaceuticals, a wholly owned subsidiary of Lotus Pharmaceuticals, has received a patent from the State Intellectual Property Office of the People's Republic of China, which covers the composition and preparation methods for controlled-release oral Gliclazide through 2030.
Subscribe to our email newsletter
Gliclazide is commonly used to control mild to moderate adult-onset type 2 diabetes.
Lotus Pharma’s new controlled-release Gliclazide tablet is formulated using osmotic pump technology, which encases the drug in a semi-permeable framework for a gradual, sustained release.
Lotus Pharma chairman and CEO Zhongyi Liu said that they believe their controlled-release Gliclazide tablet would have a meaningful impact on the clinical treatment of diabetes.
"Our controlled-release formulation has the potential to provide a more stable and sustained drug delivery compared to conventional Gliclazide, resulting in fewer side effects, greater efficacy and an improved safety profile," Liu said.